All In Biotech

Drug Trial Radar · NCT07128394

Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment

Exogenous Luteinizing Hormone Supplementation to Improve Embryo Quality in Patients With Excessive LH Suppression During a Long GnRH-Agonist Protocol: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 590 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

590

Planned (sponsor's estimate)

Start

Feb 1, 2024

Primary completion

Sep 30, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
Nanjing UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 20 years, up to 37 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized controlled trial aims to evaluate whether supplementation with exogenous luteinizing hormone (LH) can improve embryo quality in patients undergoing in vitro fertilization (IVF) with a long gonadotropin-releasing hormone agonist (GnRH-a) protocol who have excessive suppression of LH. Eligible participants will be randomly assigned to receive either exogenous LH supplementation or standard care. The primary outcome is embryo quality, and secondary outcomes include pregnancy rates and safety assessments. The study is conducted at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University.

Conditions

  • Infertility, Female
  • Luteinizing Hormone (LH)

Interventions

  • Recombinant Luteinizing Hormone (rLH)Drug

    Recombinant LH administered subcutaneously in combination with recombinant FSH (rFSH) at a ratio of 2:1 starting on stimulation day, continued throughout controlled ovarian hyperstimulation. Dosage adjusted according to follicular growth and serum hormone levels.

  • Recombinant Follicle-Stimulating Hormone (rFSH)Drug

    Recombinant FSH administered subcutaneously for controlled ovarian hyperstimulation after pituitary downregulation with a long-acting GnRH agonist. Dosage adjusted based on follicular development and hormone monitoring.

  • Gonadotropin-Releasing Hormone Agonist (GnRH-a)Drug

    Long-acting GnRH agonist (3.75 mg) administered subcutaneously on menstrual cycle day 2-4 for pituitary downregulation before controlled ovarian hyperstimulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of cycles with no usable embryosTime frame: 7 days after oocyte retrieval

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Drum Tower Hospital, Nanjing University Medical School

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.